In last trading session, Abivax ADR (NASDAQ:ABVX) saw 0.62 million shares changing hands with its beta currently measuring 0.26. Company’s recent per share price level of $9.95 trading at -$0.39 or -3.77% at ring of the bell on the day assigns it a market valuation of $631.53M. That closing price of ABVX’s stock is at a discount of -34.17% from its 52-week high price of $13.35 and is indicating a premium of 52.06% from its 52-week low price of $4.77. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.5 million shares which gives us an average trading volume of 301.19K if we extend that period to 3-months.
For Abivax ADR (ABVX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.15. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Abivax ADR (NASDAQ:ABVX) trade information
Abivax ADR’s shares saw a change of -25.97% in year-to-date performance and have moved 20.31% in past 5-day. Abivax ADR (NASDAQ:ABVX) showed a performance of 64.19% in past 30-days. Number of shares sold short was 1.26 million shares which calculate 4.83 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 22.5 to the stock, which implies a rise of 55.78% to its current value. Analysts have been projecting 12 as a low price target for the stock while placing it at a high target of 33. It follows that stock’s current price would drop -20.6% in reaching the projected high whereas dropping to the targeted low would mean a loss of -20.6% for stock’s current value.
Abivax ADR (ABVX) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -1.44% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 5.44% while estimates for its earnings growth in next 5 years are of 9.83%.
Abivax ADR (NASDAQ:ABVX)’s Major holders
Investors also watch the number of corporate investors in a company very closely, which is 50.19% institutions for Abivax ADR that are currently holding shares of the company. TCG CROSSOVER MANAGEMENT, LLC is the top institutional holder at ABVX for having 6.06 million shares of worth $80.07 million. And as of 2024-06-30, it was holding 14.0635 of the company’s outstanding shares.
The second largest institutional holder is DEEP TRACK CAPITAL, LP, which was holding about 4.18 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.7055 of outstanding shares, having a total worth of $55.26 million.
